Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 科学研究和技术服务业
Company Introduction 上海毕得医药科技股份有限公司（公司简称：毕得医药，股票代码：688073）成立于2007年，总部位于上海市杨浦区安波路创智汇，是一家以医药中间体相关产品的研发、生产、销售及合成定制为主的高新技术企业。自公司成立以来，始终坚持信誉至上，质量第一的企业信条，产品被广泛地应用于生命科学、有机化学、材料科学、分析化学与其他学科的研发及生产领域，销售范围遍及全球。目前，公司与诸多国内外顶尖的医药研发单位建立了合作伙伴关系。 公司是一家聚焦于新药研发产业链前端，依托药物分子砌块的研发设计、生产及销售等核心业务，为新药研发机构提供结构新颖独特、功能多样、品类丰富的药物分子砌块及科学试剂等产品的高新技术企业。 公司的产品主要服务于药物靶标发现，苗头化合物筛选，先导化合物发现、合成及优化，药物候选化合物发现等新药研发的关键环节。以药物构效和构性关系、药物化合物逆合成分析等理论为指导，公司多年密切跟踪药物化合物的动态，形成以药物分子砌块研发设计、定制化合成、分子结构确证、纯度检测及纯化等为代表的核心技术体系，构筑起种类全、规模大的药物分子砌块产品库，能够满足客户对药物分子砌块的高技术、多品类、微小剂量及多频次需求。公司具备向新药研发机构提供 30 万种结构新颖、功能多样的药物分子砌块的能力，其中自成立以来累计为客户提供超过 10 万种药物分子砌块产品，常备药物分子砌块库有 7 万种左右，自主研发合成的药物分子砌块达 1.2 万种。 公司的终端客户主要为新药研发企业、科研院所、CRO机构等新药研发机构，包括以罗氏（Roche）、默克（Merck KGaA）、辉瑞（Pfizer）、艾伯维（Abbvie）、吉利德（Gilead）等为代表的跨国医药企业和以恒瑞医药、百济神州、石药集团、科伦药业等为代表的境内新药研发企业；以康龙化成、美迪西、保诺-桑迪亚、GVK、Syngene等为代表的国内外CRO机构；以美国国立卫生研究院（NIH）、中国科学院上海药物研究所、中国科学院上海有机化学研究所等为代表的科研院所；以Harvard University、Yale University、Princeton University、Massachusetts Institute of Technology、清华大学、北京大学为代表的高等院校等。 公司致力于成为全球药物分子砌块领域的领先企业，积极开展全球布局，在北美、南美、西欧、东欧、中东、东南亚等新药研发高地进行布局和拓展，实现紧跟医药前沿研发方向，及时开发出结构独特、功能多样的药物分子砌块的类型，快速响应客户对药物分子砌块和科学试剂的多样化需求，助力全球新药研发机构加速新药研发进程或降低新药研发成本。
Main Business 聚焦于新药研发产业链前端，依托药物分子砌块的研发设计、生产及销售等
Legal Representative 戴岚
Top Executives
董事长：戴岚
董事：戴岚,秦存亭
独立董事：陶永平,刘志常,李健
Top 5 Shareholder
Shareholder name Nature Holding Date
戴岚限售股32.48%31/03/2026
戴龙限售股14.42%31/03/2026
舟山欣曦企业管理合伙企业（有限合伙）流通A股4.59%31/03/2026
舟山兰旦企业管理合伙企业（有限合伙）限售股+流通A股3.17%31/03/2026
中国工商银行股份有限公司－中欧医疗健康混合型证券投资基金流通A股2.89%31/03/2026
Company Secretary 王轩
Solicitors 北京国枫律师事务所
Auditors 中汇会计师事务所（特殊普通合伙）
Tel No 021-61601560
Fax No 021-61629029
Website www.bidepharmatech.com
Email ir@bidepharmatech.com
Company Address
Register: 上海市杨浦区翔殷路128号11号楼A座101室
Office: 上海市杨浦区翔殷路999号3幢6层
Listing Date 11/10/2022
Shares Capital
Shares Capital: 90,882,948
Total A Share: 90,882,948
Listed A Share: 90,882,948
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.750
DPS(RMB)* ¥ 1.160
NBV Per Share(RMB)* ¥ 22.506
Market Capitalization(RMB) 5.773B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.